Video

Dr. Fisher on Bortezomib/R-CHOP Combo for Mantle Cell Lymphoma

Author(s):

Richard Fisher

In Partnership With:

Richard Fisher, MD, president and CEO of Fox Chase Cancer Center, discusses adding bortezomib (Velcade) to the standard R-CHOP regiment (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, prednisone) for previously untreated mantle cell lymphoma.

Richard Fisher, MD, president and CEO of Fox Chase Cancer Center, discusses adding bortezomib (Velcade) to the standard R-CHOP regiment (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, prednisone) for previously untreated mantle cell lymphoma.

A phase 2 study of this combination showed promising results. While the level of toxicities were minimal during the trial, there were some cases of neurotoxicity.

Fisher says that the results of the trial show the potential of bortezomib as a treatment option for patients with mantle cell lymphoma.

Related Videos
Alan Tan, MD, genitourinary oncology and melanoma specialist, Vanderbilt-Ingram Cancer Center; associate professor, medicine, Division of Hematology Oncology, Vanderbilt University Medical Center
Zosia Piotrowska, MD, MHS, instructor, Harvard Medical School; medical oncologist, Massachusetts General Hospital
Bartosz Chmielowski, MD
Raza Hoda, MD, FASCP
Armin Ghobadi, MD, professor, medicine, Oncology, Section of Bone Marrow Transplant; clinical director, Center for Gene and Cellular Immunotherapy, Siteman Cancer Center, Washington University
Timothy S. Fenske, MD, MS
Yair Lotan, MD, professor, urology, chief, urologic oncology, Jane and John Justin Distinguished Chair in Urology, UT Southwestern Harold C. Simmons Comprehensive Cancer Center; medical director, Urology Clinic, UT Southwestern and Parkland Health and Hospital System
Roxana S. Dronca, MD, discusses the FDA’s approval of subcutaneous nivolumab across solid tumor indications.
Craig Eckfeldt, MD
Whitney Goldsberry, MD
Related Content
Zachary Frosch, MD, MSHP
January 2nd 2025

Epcoritamab Is Associated With Higher Travel Burden/Costs in R/R DLBCL and Follicular Lymphoma

USC Norris Comprehensive Cancer Center, UT Southwestern Medical Center Harold C. Simmons Comprehensive Cancer Center, Fox Chase Cancer Center, the University of Chicago Comprehensive Cancer Center
May 1st 2023

Stand Up to Cancer Grant Recipients Discuss Initiative to Expand Access to Early-Phase Clinical Trials

Fellows of the American College of Surgeons | Image Credit: © Katsyarina - stock.adobe.com
December 4th 2024

Fox Chase Cancer Center’s Dr. Anthony M. Villano and Dr. Austin D. Williams Named Fellows of the American College of Surgeons

Bekaii-Saab, George, and von Mehren Discuss Pivotal Findings in GIST, TGCT, and RAS/RAF–Mutated Solid Tumors
August 29th 2022

Bekaii-Saab, George, and von Mehren Discuss Pivotal Findings in GIST, TGCT, and RAS/RAF–Mutated Solid Tumors

Lu Chen, PhD
November 22nd 2024

Fox Chase Cancer Center Researcher Lu Chen Receives $250,000 NIH Grant to Further Investigation of RNA

Parth A. Desai, MBBS, MD
November 20th 2024

Fox Chase Cancer Center Researcher Find New Treatment Targets in Microenvironment of Small Cell Lung Cancer